Columbus Macro LLC Acquires New Holdings in Danaher Corporation $DHR

Columbus Macro LLC acquired a new position in Danaher Corporation (NYSE:DHR) in the third quarter, Holdings Channel reports. The fund acquired 23,528 shares of the conglomerate’s stock, valued at approximately $5,213,000.

A number of other hedge funds also recently bought and sold shares of the stock. Virginia Wealth Management Group Inc. bought a new position in Danaher in the third quarter worth about $12,484,000. Union Savings Bank boosted its holdings in shares of Danaher by 258.6% in the 3rd quarter. Union Savings Bank now owns 7,883 shares of the conglomerate’s stock valued at $1,746,000 after buying an additional 5,685 shares in the last quarter. Elmwood Wealth Management Inc. boosted its holdings in shares of Danaher by 73.2% in the 3rd quarter. Elmwood Wealth Management Inc. now owns 9,986 shares of the conglomerate’s stock valued at $2,212,000 after buying an additional 4,222 shares in the last quarter. Essex LLC bought a new stake in shares of Danaher in the 3rd quarter valued at about $4,692,000. Finally, Cultivar Capital Inc. purchased a new position in shares of Danaher in the 3rd quarter worth approximately $619,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. The Goldman Sachs Group raised their target price on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Evercore reaffirmed an “outperform” rating and issued a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Finally, Wells Fargo & Company reduced their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Stock Up 0.8%

Danaher stock traded up $1.81 during midday trading on Wednesday, reaching $224.65. The company’s stock had a trading volume of 3,595,884 shares, compared to its average volume of 4,457,645. The stock’s 50-day simple moving average is $212.41 and its 200-day simple moving average is $195.13. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The stock has a market capitalization of $157.93 billion, a P/E ratio of 39.90, a PEG ratio of 2.78 and a beta of 0.76.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the company earned $0.77 earnings per share. The company’s quarterly revenue was up 5.5% on a year-over-year basis. On average, sell-side analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.